- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Correction: Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo ; volume:84 ; number:6 ; day:29 ; month:5 ; year:2024 ; pages:745 ; date:6.2024
Drugs ; 84, Heft 6 (29.5.2024), 745, 6.2024
- Urheber
-
Kang, Connie
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40265-024-02055-y
- URN
-
urn:nbn:de:101:1-2409170842309.890100098477
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kang, Connie
- SpringerLink (Online service)
Ähnliche Objekte (12)
Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
Ruxolitinib-Creme - innovativer topischer Behandlungsansatz bei nichtsegmentaler Vitiligo
Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis
Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year
Circadian clock gene expression and polymorphism in non-segmental vitiligo
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
Vitiligo-Like Depigmentation following Treatment with Imiquimod 5% Cream for Condylomata Acuminata
Correction to: Evaluation of serum and tissue levels of cold‑inducible RNA‑binding protein in non‑segmental Vitiligo
Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History
A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis
Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
Ruxolitinib-Creme - innovativer topischer Behandlungsansatz bei nichtsegmentaler Vitiligo
Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis
Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year
Circadian clock gene expression and polymorphism in non-segmental vitiligo
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
Vitiligo-Like Depigmentation following Treatment with Imiquimod 5% Cream for Condylomata Acuminata
Correction to: Evaluation of serum and tissue levels of cold‑inducible RNA‑binding protein in non‑segmental Vitiligo
Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History
A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis
Ruxolitinib Cream 1.5%: A Review in Non-Segmental Vitiligo
Ruxolitinib-Creme - innovativer topischer Behandlungsansatz bei nichtsegmentaler Vitiligo
Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Short-term (24 weeks) treatment efficacy and safety of ruxolitinib cream in participants with vitiligo: a systematic review and meta-analysis
Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year
Circadian clock gene expression and polymorphism in non-segmental vitiligo
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies
Vitiligo-Like Depigmentation following Treatment with Imiquimod 5% Cream for Condylomata Acuminata
Correction to: Evaluation of serum and tissue levels of cold‑inducible RNA‑binding protein in non‑segmental Vitiligo
Efficacy and Safety of Ruxolitinib Cream in Atopic Dermatitis Based on Previous Medication History